Latest XVIVO News & Updates

See the latest news and media coverage for XVIVO. We track all announcements, press releases, and industry mentions in real time, all in one place.

XVIVO

Organ perfusion technologies provider

xvivogroup.com

Headquarters: Mölndal, Sweden
Founded year: 1998
Company type: Public company
Number of employees: 50–300
Industry: Medical Equipment, Supplies & Distribution

Last updated Today

Latest news about XVIVO

In short: XVIVO reported strong financial growth and received critical regulatory approvals for its heart and lung preservation technologies in 2026.

Company announcements

July 14 XVIVO

XVIVO's net sales grew 34 percent in Q2

EBITDA margin improved to 19 percent, cash flow from operations was SEK 63.5 million.

May 18 XVIVO

XVIVO's heart technology gets regulatory derogation and reimbursement in France

The derogation enabled 11 heart transplants at Hôpital La Pitié-Salpêtrière. Reimbursement now allows broad national use.

May 8 XVIVO

XVIVO’s Liver Assist boosts liver transplants 70%

Sir Charles Gairdner Hospital in Australia adopts combined perfusion technology, increasing transplants and reducing waitlist mortality since 2025.

April 27 XVIVO

XVIVO holds Annual General Meeting

Resolutions include adopting 2025 financials, no dividend, board re-elections, new incentive program, and share issue authorizations.

Media coverage

July 30 Digital Health

NICE backs lung preservation machine for NHS use

A specialist machine designed to keep donated lungs functioning outside the body has been conditionally recommended by NICE.

July 14 FinanzNachrichten.de

XVIVO Perfusion AB: Interim Report January - June 2026

GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding...

July 14 Yahoo Finance

Xvivo Perfusion AB (XVIPF) Q2 2026 Earnings Call Highlights: Strong Organic Growth Amidst ...

Net Sales: SEK239 million, representing 36% organic growth in local currencies. EBITDA: SEK45 million, with an EBITDA margin of 19%. Gross Margin: 71% overall; Thoracic...

July 9 Yahoo Finance

OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S.

OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ...

Never miss news about XVIVO

Track XVIVO and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.